Comparative analysis of the levels of soluble forms of receptor and ligand of the immunity control point PD-1 / PD-L1 in the blood serum of patients with typical bone osteosarcoma and chondrosarcoma

2020 ◽  
Vol 65 (11) ◽  
pp. 669-675
Author(s):  
Nikolay Evgenievich Kushlinskii ◽  
A. A. Alferov ◽  
I. V. Boulytcheva ◽  
Yu. S. Timofeev ◽  
E. A. Korotkova ◽  
...  

Results of ELISA investigation of the pretreatment sPD-1 and sPD-L1 content in blood serum of 133 bone neoplasms patients aged 6-70 years and 57 practically healthy control persons aged 12-70 years are described. In 14 patients the neoplasms were of a benign character, in 16 - borderline giant-cell bone tumor was diagnosed, and in 103 - malignant bone lesions including 39 osteosarcomas and 42 chondrosarcomas were revealed. The sPD-1 receptor concentrations in blood serum did not differ between control healthy persons and primary bone tumor patients, while serum sPD-L1 level in bone tumor patients was statistically significantly increased (p<0.0000001). By means of ROC curve construction a cut-off sPD-L1 level of 16.5 pg/ml was found that imposed 75,9% sensitivity and 75,4% specificity in relation to healthy control. However, the frequency of sPD-L1 levels exceeding 16.5 pg/ml was approximately similar in benign, borderline and malignant bone tumor patients. Analysis of the pattern of sPD-1 and sPD-L1 circulation in the peripheral blood of patients with the most prevalent malignant bone tumors - osteosarcoma and chondrosarcoma - demonstrated that in both sarcoma types sPD-L1 level was significantly higher than in control, but in patients with chondrogenic tumors the soluble ligand sPD-L1 dominates in the circulation, while in those with osteogenic tumors - sPD-1 receptor prevails. In particular, sPD-1 level is statistically significantly higher in patients with typical osteosarcoma than in those with typical chondrosarcoma (p=0.002437), and sPD-L1/sPD-1 concentration ratio in chondrosarcoma is highly significantly more than 2-fold higher than in osteosarcoma (0.81 and 0.35 respectively; p=0.000284). The sensitivity of sPD-L1 ≥16.5 pg/ml test in typical osteosarcoma patients’ group comprised only 70.2%, and in those with typical chondrosarcoma - 84.6%. Serum sPD-1 and sPD-L1 concentrations in osteosarcoma and chondrosarcoma patients were not associated with the indices of tumor advancement, its histological grade, localization in the osseous system, and type of affected bone. Thus, it can be concluded that the ratio between circulating soluble forms of the receptor and the ligand of PD-1/PD-L signaling pathway differs between patients with chondrogenic and those with osteogenic tumors, sPD-L1 being diagnostically valuable mostly for chondrogenic bone neoplasms.

2021 ◽  
Vol 66 (9) ◽  
pp. 533-538
Author(s):  
N. E. Kushlinskii ◽  
Olga Vladimirovna Kovaleva ◽  
Yu. B. Kuzmin ◽  
E. A. Korotkova ◽  
E. S. Gershtein ◽  
...  

The data of a comparative enzyme-linked immunosorbent assay of the content of the soluble form of the immunity checkpoint VISTA in the blood serum of 30 healthy donors (control group), 79 patients with primary malignant (osteosarcoma - 30, chondrosarcoma - 31, chordoma - 14) and 14 borderline (giant cell tumor) bone neoplasms are presented. In the general group of patients with malignant neoplasms of bones, the median sVISTA content in blood serum is statistically significant lower than in the control (p = 0.040). In patients with bone tumors and healthy donors over 18 years of age, there was a decrease with age in serum sVISTA levels. There were no significant differences in sVISTA concentration between patients with osteosarcoma, chondrosarcoma and healthy donors. Only in patients with chordoma were sVISTA levels statistically significant lower than in controls (p = 0.013). In the groups of patients with chondrosarcoma and osteosarcoma of the bone, there were no significant associations between the serum sVISTA content and the main clinical and morphological characteristics of the disease. In patients with osteosarcoma, no relationship was found between sVISTA levels and overall survival rates, while in patients with bone chondrosarcoma, there was a tendency towards a favorable prognosis with a high content of the marker in the blood serum.


Author(s):  
N.E. Kushlinskii ◽  
I.S. Chernomaz ◽  
E.S. Gershtein ◽  
I.V. Boulytcheva ◽  
M.D. Aliev ◽  
...  

2019 ◽  
Vol 23 (01) ◽  
pp. 003-018 ◽  
Author(s):  
Amanda Isaac ◽  
José Villagrán ◽  
P. Afonso

Chondroid tumors are a heterogeneous group of neoplasms that all share the production of chondroid matrix. This ranges from a fetal type to mature hyaline cartilage and mirrors its imaging characteristics.The benign chondroid tumors represent some of the most encountered incidental bone lesions, with osteochondroma the most frequent benign bone tumor. Enchondroma is mostly asymptomatic, and yet it is probably the second most common primary bone tumor. Similarly, its malignant counterpart, chondrosarcoma, is the second most common malignant primary bone tumor.The 2013 World Health Organization (WHO) updated this group of tumors, and grade 1 chondrosarcoma was renamed “atypical cartilage tumor” and classified as an intermediate type of tumor, not a malignancy, which better describes its clinical behavior.In this article we summarize changes made in the updated 2013 WHO classification and highlight the diagnostic features differentiating an enchondroma from a low-grade chondrosarcoma. We also describe practical imaging aspects of the remaining chondroid tumors.


2007 ◽  
Vol 88 (7) ◽  
pp. 885-890 ◽  
Author(s):  
Axel Hillmann ◽  
Roger Weist ◽  
Albert Fromme ◽  
Klaus Völker ◽  
Dieter Rosenbaum

Bone Reports ◽  
2020 ◽  
Vol 13 ◽  
pp. 100421
Author(s):  
Valérie Trichet ◽  
Louis-Romée Le Nail ◽  
Régis Brion ◽  
Françoise Rédini ◽  
François Vallette ◽  
...  

2018 ◽  
Vol 40 (7) ◽  
pp. 555-557
Author(s):  
Daniel Koh ◽  
Theodore Lau ◽  
Evonne Teoh ◽  
Kenneth K. Lau

Sign in / Sign up

Export Citation Format

Share Document